#VisualAbstract: Lecanemab reduced cognitive and functional

#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer's disease compared to placebo

1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to

Related Keywords

, Minute Medicine Inc , Rating Level , Wechsler Memory Scale , Logical Memory , Clinical Dementia Rating ,

© 2025 Vimarsana